Teva Pharmaceutical (TEVA) Misses Q4 EPS by 1c

Teva Pharmaceutical (NYSE: TEVA) reported Q4 EPS of $1.32, $0.01 worse than the analyst estimate of $1.33. Revenue for the quarter came in at $5.2 billion versus the consensus estimate of $5.26 billion.

For earnings history and earnings-related data on Teva Pharmaceutical (TEVA) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• McDonald’s said to plan value strategy overhaul to revive US sales growth
• AM Best Revises Outlooks to Positive for Triangle Insurance Company
• Faraday Future says it regained Nasdaq compliance after equity shortfall